{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Newark",
      "state": "DE",
      "country": "United States",
      "classification": "Class I",
      "openfda": {
        "application_number": [
          "NDA022433"
        ],
        "brand_name": [
          "BRILINTA"
        ],
        "generic_name": [
          "TICAGRELOR"
        ],
        "manufacturer_name": [
          "AstraZeneca Pharmaceuticals LP"
        ],
        "product_ndc": [
          "0186-0776",
          "0186-0777"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "TICAGRELOR"
        ],
        "rxcui": [
          "1116635",
          "1116639",
          "1666332",
          "1666334"
        ],
        "spl_id": [
          "c664bf3d-f861-4588-afbf-c3c52f1ae430"
        ],
        "spl_set_id": [
          "f7b3f443-e83d-4bf2-0e96-023448fed9a8"
        ],
        "package_ndc": [
          "0186-0777-08",
          "0186-0777-60",
          "0186-0777-18",
          "0186-0777-39",
          "0186-0777-28",
          "0186-0776-60",
          "0186-0776-94"
        ],
        "is_original_packager": [
          true
        ],
        "nui": [
          "N0000182142",
          "N0000008832",
          "N0000182143",
          "N0000182141",
          "N0000185503"
        ],
        "pharm_class_epc": [
          "P2Y12 Platelet Inhibitor [EPC]"
        ],
        "pharm_class_pe": [
          "Decreased Platelet Aggregation [PE]"
        ],
        "pharm_class_moa": [
          "P2Y12 Receptor Antagonists [MoA]",
          "Cytochrome P450 3A4 Inhibitors [MoA]",
          "P-Glycoprotein Inhibitors [MoA]"
        ],
        "unii": [
          "GLH0314RVC"
        ]
      },
      "product_type": "Drugs",
      "event_id": "77336",
      "recalling_firm": "AstraZeneca Pharmaceuticals, LP",
      "address_1": "587 Old Baltimore Pike",
      "address_2": "",
      "postal_code": "19702-1307",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Nationwide in the USA and Puerto Rico to physician offices.",
      "recall_number": "D-0958-2017",
      "product_description": "BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",
      "product_quantity": "40,368 bottles",
      "reason_for_recall": "Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",
      "recall_initiation_date": "20170525",
      "center_classification_date": "20170711",
      "termination_date": "20180424",
      "report_date": "20170719",
      "code_info": "Lot # JB5047, Exp 10/19",
      "more_code_info": ""
    }
  ]
}